February 13, 2020 / 2:03 PM / 8 days ago

BRIEF-Cortexyme Provides Regulatory Update For COR388 Development Program In Alzheimer’S Disease

Feb 13 (Reuters) - Cortexyme Inc:

* CORTEXYME PROVIDES REGULATORY UPDATE FOR COR388 DEVELOPMENT PROGRAM IN ALZHEIMER’S DISEASE

* CORTEXYME INC - INTERIM ANALYSIS IN PHASE 2/3 GAIN TRIAL EXPECTED TO OCCUR IN Q4 2020

* CORTEXYME INC - CORTEXYME CONTINUES TO EXPECT GAIN TRIAL’S FINAL ANALYSIS IN Q4 OF 2021. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below